XTX Topco’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

XTX Topco’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-71,040	Closed	-$682K	–	3294
2024 Q4	$682K	Sell	71,040 -111,848	-61%	-$584K	0.06%	521
2024 Q3	$523K	Buy	182,888 +58,587	+47%	+$181K	0.04%	786
2024 Q2	$363K	Buy	124,301 +33,651	+37%	+$92K	0.03%	841
2024 Q1	$289K	Buy	90,650 +75,984	+518%	+$253K	0.04%	887
2023 Q4	$49.3K	Sell	14,666 -26,116	-64%	-$67.3K	0.01%	1235
2023 Q3	$97.1K	Sell	40,782 -192,711	-83%	-$404K	0.02%	1190
2023 Q2	$411K	Buy	233,493 +82,404	+55%	+$210K	0.07%	503
2023 Q1	$465K	Buy	151,089 +27,053	+22%	+$162K	0.1%	337
2022 Q4	$657K	Buy	124,036 +107,856	+667%	+$493K	0.14%	194
2022 Q3	$57K	Buy	+16,180	New	+$53.5K	0.01%	1011

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

XTX Topco's PSTX Position: Q1 2025 in Review

XTX Topco sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 71,040 shares — an estimated $682K sold.

XTX Topco first reported a position in PSTX in Q3 2022 and held it in 10 quarters. The position peaked at $682K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

XTX Topco reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
XTX Topco sold 71,040 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $682K.
XTX Topco first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 10 quarters.
XTX Topco's Poseida Therapeutics, Inc. Common Stock position peaked at $682K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on XTX Topco's 13F filing for Q1 2025, filed 8 May 2025.